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ABSTRACT
The aim of this review is to identify peoples’
perspectives of their glucose-lowering and anti-
obesity drugs in relation to diabetes and weight
control and to explore how these views affect
medication adherence. Theoretical perspectives
associated with medicine-taking behavior are
also explored. The systematic review was based
on a meta-ethnography of qualitative studies
identified through a search of 12 medical and
social science databases and subsequent citation
searches. The quality of all studies was assessed.
Sixteen studies were included with data from
360 UK individuals. No relevant studies were
identified which focused on anti-obesity and
non-insulin injectable drugs. The review
revealed that the patients’ perspectives and
emotional state were influenced by starting
and/or changing to a new glucose-lowering
medicine. These were also influenced by prior
medication experience, disease perceptions and
interactions with clinicians. Despite reports of
positive experiences with and positive percep-
tions of medicines, and of participation in
strategies to regain life control, medication
non-adherence was common. Accepting glu-
cose-lowering medicines impacted on the indi-
vidual’s perception of lifestyle changes, and it
was notable that weight loss was not perceived
as a strategy to support diabetes management.
Synthesis revealed that more than one theory is
required to explain medicine-taking behavior.
New insights into the underlying factors of poor
adherence and the specific practical issues
identified in this review can help in the devel-
opment of patient-centered interventions.
Funding: Diabetes UK.
Keywords: Medication adherence; Meta-
ethnography; Patient perspectives; Systematic
review; Type 2 diabetes medicines; Weight loss
INTRODUCTION
Type 2 Diabetes mellitus (T2DM) is a major
global public health problem, with over 80% of
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this population in the UK being either over-
weight or obese [1]. Long-term hyperglycemia
(glycated hemoglobin [HbA1c][8.0%,
64 mmol/mol) and weight gain increase the risk
of disabling secondary complications. There-
fore, body weight and glycemic control are
important targets in managing T2DM [2].
Despite the availability and effectiveness of
glucose-lowering and anti-obesity drugs (GLDs
and AODs, respectively) systematic reviews
show that patients with T2DM rarely adhere to
their medication [3–5], and currently there are
no effective interventions that consistently
support and improve adherence in this group of
patients [6–8]. The term ‘‘adherence’’ is used in
this review, but due to the absence of a uni-
versally acceptable standardized definition in
the literature [9, 10], its use can be problematic.
Here we focus on the extent to which patients
intentionally or unintentionally adhere to their
medication as prescribed. Medicine-taking
behavior among diabetes patients is complex
and multifactorial [10–12], while patterns of
adherence can be determined as early as at the
point of prescription [11]. Medication non-ad-
herence has implications for patients as it may
mean a lost opportunity for health gain [13] or
more rapid disease progression which risks fur-
ther intensive medical intervention, alongside
the financial burdens this can impose on
healthcare budgets.
An abundance of research and systematic
reviews have explored the perception of
medicines or medication adherence in people
with diabetes, yet these lack a sole focus on
T2DM medicines and methodological rigor and
are diverse in terms of study design, population
and settings [14–24]. Healthcare systems across
and within countries vary in their diabetes care
delivery, particularly regarding HbA1c targets,
availability and/or licences of prescribed drugs,
the use of which is also influenced by guidelines
and cost. The UK is one of the few countries
where people with diabetes are exempt from all
prescription charges [25].
The aim of this systematic review is to
identify the perspectives of UK patients regard-
ing their T2DM medicines (GLDs and AODs)
and to determine how these perspectives influ-
ence adherence. As the array of T2DM
medicines has increased over the last few years,
many of which have potential for both weight
loss and diabetes control, in either oral or
injectable form, in this review we explore whe-
ther the medicine’s effect on diabetes and body
weight affected the perspectives and adherence
of patients. People with T2DM experience many
changes in diabetes medications over a lifetime
of diabetes and, therefore, in this review we also
focus on whether patients’ views change over
time or between treatment changes. A sec-
ondary objective was to identify the optimal
research designs and theoretical perspectives for
studying beliefs, attitudes and medicine-taking
behaviors in this patient population.
METHODS
Noblit and Hare’s meta-ethnographic approach
[26] using the seven-steps method (Fig. 1) was
used in this review. Highly relevant subsequent
adaptations to this approach related to medi-
cine-taking and/or diabetes management
[14, 27, 28] also informed the methodology.
The review is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
Search Strategy
Electronic databases (Cochrane Library, DARE/
CRD/NHS (via http://www.crd.york.ac.uk),
PROSPERO, Web of Science, SCOPUS, Science-
Direct, PsychINFO, CINAHL Plus, MEDLINE,
EMBASE, AMED, EBSCO) were searched from
inception to February 2016 (full strategy is
shown in the Electronic Supplementary Mate-
rial [ESM]). A broad and specific approach was
used to identify studies based on a combination
of the following search terms: ‘‘type 2 diabetes,’’
‘‘medication-taking,’’ ‘‘adherence,’’ ‘‘compli-
ance,’’ ‘‘treatment,’’ ‘‘medication,’’ ‘‘oral hypo-
glycemic drugs/agents,’’ ‘‘anti-obesity drugs,’’
‘‘insulin,’’ ‘‘beliefs,’’ ‘‘attitudes’’ and ‘‘weight.’’
The references of all retrieved articles were
checked for relevant studies.
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Study Selection
Published studies in English in which the
methodology included a qualitative data col-
lection and analysis with a primary focus on
medication-taking behavior or beliefs/attitudes
towards GLDs and/or AODs were included in
the review. Mixed-method studies reporting
qualitative data were also included. Studies were
selected if the participants were (1) adults
([18 years) with T2DM, (2) using pharma-
cotherapy to manage diabetes and/or weight
and (3) managed in the UK (primary care or an
outpatient clinic in secondary care). Studies
were excluded if participants had gestational
diabetes or were hospitalized, or they included
all types of diabetes and types of therapies but
did not focus on the above criteria in a sub-
group analysis. The lead author (AP) performed
the systematic literature search, of which a
sample was verified by the second author (HC).
This process involved screening papers by title,
abstract and full text. Discrepancies were
resolved through consensus. A further three
studies were identified following screening of
individual studies from two systematic reviews
[20, 24] as they were eligible for this review. The
review followed the Preferred Reporting Items
for Systematic Reviews and Meta-Analysis
(PRISMA) checklist for the selection of studies
(Fig. 2).
Quality Assessment
Included studies were assessed for quality using
the Critical Appraisal Skills Program (CASP)
criteria for qualitative research [29], with an
additional question regarding each study’s the-
oretical perspective, as illustrated elsewhere
[30]. To ensure rigor (see ESM), articles were
included only if they scored C 7 (maximum
score 11), resulting in one article being exclu-
ded at this stage (Fig. 2). One author (AP) criti-
cally appraised all studies, and a sub-sample was
checked by a second author (HC). Both AP and
HC examined papers with low CASP score to
reach a consensus.
1. Geng Started
2. Deciding what is relevant
3. Reading the studies
4. Determining how studies are related
5. Translang the studies into one 
another (reciprocal/refutaonal)
6. Synthesizing translaons 
(line-of-argument synthesis)
Idenfying topic that qualitave research will inform
Selecng research relevant to the topic of interest, set inclusion 
and exclusion criteria
Crical appraisal of retrieved studies, Repeated reading of studies 
and nong metaphors, inial extracon of data
Organizing papers into medicine groups, creang a list of 
metaphors, key phrases, concepts for each account
The metaphors and/or concepts in account are compared with 
other accounts ﬁrst within medicine groups and then across 
groups. Inial producon of medicine map
Analyzing compeng interpretaons to produce new 
interpretaon/ conceptual development- inial producon of 
ﬁnal model
7. Expressing Synthesis Communicang and presenng synthesis- publicaon
Fig. 1 Seven-step meta-ethnography [26]
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Data Synthesis
Papers reporting data from the same research
study were collated as one. None of the eligible
studies reported views on AODs and non-in-
sulin injectable medicines. Papers were sepa-
rated into four research-focus groups, namely,
oral GLDs (OGLDs), insulin, diabetes medicines
(OGLDs and insulin) and polypharmacy/multi-
morbidity, using the chronological approach to
form the synthesis [28]. For example, articles
which only described participants’ experiences
with OGLDs were part of the first group and
were synthesized chronologically. First- and
second-order constructs (i.e. direct quotes from
participants and interpretations of authors)
were extracted by AP using a spreadsheet to
manage the synthesis process. Second-order
constructs retained the terminology of the
authors who published the study to preserve the
meaning and context of their findings. Themes
were separated into two categories of views and
experiences, namely, prior to and after initia-
tion of a medication treatment, to identify
changes in participants’ views about their
medicines and their medication-taking behav-
ior over time. Themes also included passages
related to quality of care and weight to identify
whether these aspects influenced medicine-
taking behavior, although these did not repre-
sent third-order constructs. The studies were
then translated into each other, one by one, to
form a reciprocal (i.e. similar findings) or refu-
tational (i.e. contradictory findings) synthesis
[26, 30]. Briefly, the synthesis of the first two
papers was compared with the third paper, and
this process continued until all studies were
translated into each other. This process was
done separately for the ‘‘OGLD’’ and ‘‘insulin’’
groups. The findings from the ‘‘diabetes
medicines’’ and ‘‘polypharmacy/multimorbid-
ity’’ groups were then compared with each of
the first two groups where relevant. In the pro-
cess of comparing the studies against each
other, explicit differences among the studies
were noted (Table 1). Finally, a ‘‘line-of-argu-
ment’’ synthesis [26] was constructed by devel-
oping an overarching model that linked the
Fig. 2 Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) ﬂowchart
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translations and authors’ interpretations to
address the aims of the review.
RESULTS
Study and Participant Characteristics
A total of 16 studies were reviewed (reported in
19 papers) (Table 1) using data from 360 indi-
viduals, mostly of Caucasian (n = 133) and
South Asian origin (n = 122), all of whom were
recruited from different UK regions, both in
primary (n = 9) and secondary (n = 7) care.
Participants (aged 21–89 years) had T2DM for a
maximum of 35 years although their glycemic
control and body mass index (or body weight)
were rarely reported, except where details were
extracted from a clinical trial [31] associated
with one of the studies [40, 41].
Two studies employed a longitudinal study
design to identify changes in participants’ views
[34, 36]; however only one analyzed data lon-
gitudinally [34]. While the behavioral and social
theories identified were linked to individuals’
health-related behavior, the studies did not
provide much detail beyond stating the theory
applied.
Medicine Types
The studies examined in general various issues
around the use of OGLDs and insulin, but none
specifically addressed other injectable or OGLDs
(i.e. glucogen-like peptide-1 [GLP-1] agonists,
dipeptidyl peptidase 4 [DPP-4] inhibitors, or
sodium/glucose cotransporter 2 [SGLT-2] inhi-
bitors) or AODs (i.e. orlistat). One participant
was taking insulin along with exenatide, a GLP-
1 analog; however, the focus of that study was
solely on insulin [43]. Medication name or
regime was rarely reported, except where par-
ticipants’ quotes indicated multiple use of dia-
betes and non-diabetes medicines or specified
generic drug names.
Studies related to participants’ views follow-
ing the initiation of insulin therapy included
those involving participants who took insulin
for at least 1 month [36] as well as those in
which the participants were taking insulin for
more than 2 years [37, 40, 41]. Studies related to
barriers and refusal to initiate insulin therapy
included participants who had either refused
insulin in the last 3–6 months [38, 42] or had
started insulin within 6 months [42]. Two
studies [39, 43], related to perceptions about
insulin, included individuals who either were
already taking insulin (0.4–22 years) or were
insulin naı¨ve, while only two studies specific to
OGLD treatment specified treatment duration
(0.3–10 years) [33–35, 39].
Data Synthesis
The reciprocal synthesis (Fig. 3) shows a time-
line illustrating patients’ emotions arising from
the prospect of initiating T2DM medication,
including their perceptions of T2DM and
respective medicines and their expectations of
these medicines, as well as how these related to
outcomes such as patterns of medication-taking
and lifestyle behavior. The line-of-argument
synthesis (Fig. 4) demonstrates the key pro-
cesses to understanding patients’ journeys in
medication management.
Negative Emotional Impact
Devastation, shock, anger and disappointment
were the major emotions which appeared with
the prospect of taking medicines
[32, 34, 36, 37, 40, 48]. Starting OGLD therapy
was linked to becoming a ‘‘sick person’’ [32, 34]
and entering ‘‘a slippery slope’’ [34] leading to
taking insulin, often associated as ‘‘the last
resort’’ [38, 39, 43]. Patients referred to being
‘‘defeated’’ and letting themselves down by fail-
ing to self-manage their diabetes and diabetes
treatment [34, 37, 39, 42]. Personal failure also
emerged when patients were advised to start
insulin therapy, mainly when initiation was
imminent [37], and because they would be
judged by others as a ‘‘bad diabetic’’ [48].
My Diabetes is Serious
Over time patients, particularly if symptomatic
[48], rationalized that diabetes is a progressive
1800 Diabetes Ther (2018) 9:1791–1810
Fig. 3 Medicine map-reciprocal synthesis. OGLD Oral glucose-lowering drug, HbA1c glycated hemoglobin, T2DM type 2
diabetes mellitus
Fig. 4 Line-of-argument synthesis. HPs Health professionals
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disease [32, 34, 49], believing that lifestyle can
cause it but cannot cure it [35], ‘‘…no matter
how careful you are’’ [32]. This group of
patients, many of whom were aware of T2DM
and its treatment from family members [45],
placed importance on the role of medicines in
managing diabetes [36, 37, 39, 48, 49]. Once
they had initiated medicines, they expressed
the view that they would have to take them for
the rest of their life [32, 49, 50], otherwise, they
would ‘‘risk dying’’ [32]. This view was reinforced
by self-regulation strategies which supported
the acceptance of new medication prescriptions
(top box, Fig. 3). The combination of results
from blood glucose testing and their own
observations over time of an increase in the
number of diabetes tablets and doses were good
indicators of deteriorating diabetes despite
adherence to treatment [40, 43], justifying for
some that eventual insulin treatment was an
integral part of diabetes. Nonetheless, for oth-
ers, blood glucose testing [34, 45] (bottom box,
Fig. 3), over time, proved that medicines had
helped with blood glucose control
[34, 36, 41, 45] if they were asymptomatic or
‘‘unconvinced’’ of the medicine’s effectiveness,
reinforcing their perceptions and positive
experiences. In contrast, some on insulin ther-
apy felt frustrated when they could not see the
results of their efforts to achieve good diabetes
control [37].
My Diabetes is Not Serious
In our review this group of patients consists of
those prescribed OGLDs but who had either no
experience of taking insulin or were advised to
take insulin but refused to do so
[33, 35, 38, 39, 42–44]. These patients did not
want to actively think about their diagnosis
[34, 45], denying the possibility of future com-
plications [46] or believing these are not immi-
nent and believing that their diabetes is
‘‘insignificant’’ [33] if symptoms ceased after
being prescribed OGLDs or if T2DM was man-
aged with tablets [37, 38, 42, 43, 48]. Insulin
was an indicator of the worse type of diabetes
[37–39] and associated with more side effects
than the tablets [39], and the reluctance to
initiating insulin therapy was associated with
negative stigma (Section Perceptions and Expe-
riences of Medicines) and past medication
experiences, particularly if OGLDs were per-
ceived unsuccessful in diabetes management
[38]. Additionally, Lawton et al. [33] suggested
that the type and location of care can change an
individual’s perception of his/her diabetes,
where care provided by the general practitioner
is perceived as less serious than hospital care.
Expectations of Medications and Care
Key motivators for accepting diabetes medicines
included instant success, specifically with an
injectable treatment, and benefits of both
weight loss and diabetes control [35, 43]. Gen-
erally, individuals wished to consult a health-
care profession who they considered to be an
expert or trustworthy, an individual who they
trusted would prescribe medications appropri-
ately [32, 33, 39, 45], and they wished for con-
tinuity of care between healthcare services and
health professionals (HPs) [37].
Patients’ information needs were found to be
high [34, 35, 49, 50], despite expecting an
ongoing prescription [33, 34] and not ques-
tioning medication changes [34]. They pre-
ferred non-judgmental guidance [34] on
alleviating negative medication experiences and
managing missed doses and information that
uses ‘‘layman’s’’ language [45, 50]. Specific to
insulin, they wanted to know the advantages
and disadvantages of taking insulin [37, 43, 48],
what type and how many doses are required to
control diabetes and if any changes are required
in these [36, 39, 41], how to inject insulin cor-
rectly and guidance on dietary changes [39].
They also wanted to be better informed about
the need for their medicines, particularly if they
hold negative views about them [49].
Perceptions and Experiences of Medicines
Patients’ positive medication experiences rein-
forced positive perceptions that medications are
beneficial, effective, relieve symptoms and pre-
serve health [32, 34, 36, 37, 39, 41, 49]. When
medication effects were seen over time [36, 41],
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some patients indicated that medicines were
more effective than lifestyle measures
[34, 35, 49], prioritizing certain T2DM medici-
nes over others [32, 49, 50] and reporting
insulin being better than tablets [37, 39].
However, medications were unnatural
[32, 34, 36, 46]. Therefore, those taking multiple
medicines (whether on complex diabetes and
non-diabetes medication regimes) were worried
these could counteract their individual effects
[32] or ‘‘that’s three lots attacking the kidney’’ [34],
resulting in long-term health damage
[32, 34, 46]. They wished to minimize the daily
medication numbers or simplify the regime to
help overcome their ongoing concerns and
cope with the demands of self-managing dia-
betes [50].
Moreover, insulin was perceived negatively
by all patients whether they refused it or not,
with many expressing they would rather take
more OGLDs than inject insulin [43]. Common
worries were needle anxiety [36, 38–41, 48], fear
of consequences/complications of permanently
taking injections [37, 43], fear of weight gain or
inability to lose weight [38, 42] and fear of
hypoglycemia [37–39, 42]. Insulin was per-
ceived as restricting and interfering with their
lives [38], including daily and social activities
and traveling [37–39, 42], and with increased
dependence on others [38, 39]. Those partici-
pants who were experienced with insulin ther-
apy reported that they had lost their identity
and normality [36, 48], found it harder to self-
manage diabetes [37] and worried about inject-
ing in public, particularly if they needed to
inject with meals. Insulin was also perceived as
a threat [36, 39, 42], often used by HPs to
encourage patients to better control their dia-
betes. However, insulin perception transformed
into ‘‘punishment’’ [37] for those starting insulin
due to its association with negative stigma
[37, 43] and the belief it was unjust [36], per-
haps originated from the way it was introduced.
Patterns of Medicine-Taking Behavior
and Associated Strategies
Overall, five adherence patterns were identi-
fied (Fig. 3). There were those who fully adhered
to diabetes medicines and who strongly
believed in the positive aspects of these medi-
cines. However, they felt guilty when they
unintentionally non-adhered to their medicines
[33, 34, 41, 49] due to forgetfulness, broken
routines, being asymptomatic and confusion
when taking multiple medicines [34, 41].
Adherent and unintentional non-adherents
adopted strategies to promote adherence, such
as establishing routines that included identify-
ing logistics of where and when to inject, using
visual and family reminders, using medication
boxes or carrying medicines with them or
receiving group support [34, 37, 41].
Conversely, there were some patients who
unintentionally non-adhered to medicines due
to forgetfulness, who did not appear to feel
guilty about that behavior, perhaps due to lack
of symptoms and their belief that diabetes is not
a serious condition [33]. In those who exem-
plified intentional non-adherence, guilt was
also rarely present [34]. Reasons for non-adher-
ence included strong negative perceptions of
their medication, such as insulin stigma [41],
adverse effects [32, 33] and the medication
being detrimental to health [32, 50]. Strategies
of intentional non-adherents included adjust-
ing doses, delaying or omitting taking the
medicines altogether [32, 34, 35, 41, 50], often
manipulated by using self-monitoring of blood
glucose and/or diet, because they believed that
medicines work instantly by alleviating symp-
toms [32, 35]. HPs also indirectly influenced
medication-taking behavior if they had in the
past advised patients to adjust medicines; so in
similar situations, patients were adjusting doses
without seeking medical advice [32]. For those
taking insulin, strategies included talking to
friends and family about T2DM and treatment
of hypoglycemia [37, 39] by regularly referring
to written material and actively seeking further
information on diabetes treatments [37], often
encouraged by their family [36, 37]. They
manipulated their diet by eating more often to
avoid feeling weak, which according to the
authors was unlikely to be linked with low
blood glucose [46], or restricted social activities
such as eating out to avoid injecting in public
[41].
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Lifestyle Behavior and Weight
Management
Great importance to lifestyle measures was
given by those who perceived their diabetes as
serious and who had converted to insulin [35],
by strictly following a healthy eating plan
[37, 39] or using a moderate approach to eating
‘‘…a little bit of what you fancy’’ [48]. In contrast,
others could not identify if any changes to their
lifestyle had an impact on diabetes control and
were uncertain of their diet’s effectiveness [45],
struggling to keep up with the diet and physical
activity [33, 35, 37, 44]. Yet others indicated
that the lifestyle and medication are two alter-
native ways in which they could self-manage
diabetes, suggesting that once you take
medicines they could eat what they want
[35, 39, 48], particularly when on insulin [39].
Concerns of weight gain were apparent, but
these were not linked to diabetes medicines,
except when fear of weight gain was associated
to the refusal to initiate insulin therapy
[38, 42, 46]. Hence, weight was related to life-
style measures, even though many patients
were ‘‘naughty’’ and ‘‘cheating’’ [33] or were
unsure how to reduce calories [39]; they felt
misunderstood by HPs in relation to the diffi-
culties they faced [44, 47] with following the
recommended diet. Conversely, others sug-
gested that they would lose weight if they were
to avoid taking medicines [35, 49], although not
all believed that it would be diabetes medicines
[49].
Line-of-Argument Synthesis
Patients’ journeys started either at the time of
diagnosis and/or at the time of medication
prescription, both creating grief reactions. As
patients progressed from diet to tablets to
insulin, their emotional reactions were pro-
gressively stronger and impacted upon the way
they coped. However, perceptions of diabetes
severity appeared to change over time and were
influenced by their community and family
experiences [36, 38, 39, 43, 45], the presence/
lack of diabetes symptoms and complications
[33, 35, 37, 43, 45–48] and their own
medication beliefs. Taken together, beliefs and
emotions reinforced an evaluation of oneself,
leading to either accepting or denying the ‘‘al-
tered self-image’’ [36]. Generally, acceptance to
change meant that medicines were accepted as
part of the successful management of diabetes.
However, resistance to change did not neces-
sarily mean resistance to taking medicines.
Medication-taking and lifestyle behavior
coupled with self-regulation strategies were all
tactics patients engaged to regain self-control.
These were often associated with patients’
treatment adherence or non-adherence
[34, 35, 41, 49] and to being passive or active
[34, 36, 43] in self-managing diabetes, terms
commonly used in clinical research and prac-
tice. However, for patients these strategies are
rational decisions/actions enabling them to live
as normally as possible and to minimize the
impact of their diabetes and medicines in
everyday life.
Patients were committed to taking medicines
[34, 37] with a ‘‘sense of growing confidence’’ [36]
and were making conscious and deliberate ‘‘ef-
fort’’ [37, 41] to find out about diabetes and
adapt their daily practices to fit medication,
with some ‘‘requesting’’ or ‘‘negotiating’’ their new
regime [34, 41]. Still others reported feeling
‘‘powerless’’ [36], conveying ‘‘worry’’ [39] because
they had ‘‘tried hard’’ [37] but had been unable
to make successful changes. Hence, the experi-
ence of successful and unsuccessful practices
reinforces or undermines patients’ T2DM treat-
ment beliefs and leads yet again to a re-evalua-
tion of self.
DISCUSSION
This synthesis identified that patients associate
T2DM severity with both their treatment (life-
style vs. medicine) and prescribed medicine
(tablet vs. insulin). The results suggest that the
experience of starting or changing to a new
diabetes medication results in a self-re-evalua-
tion that the patient can either accept or deny.
The re-evaluation of self is an endless cyclical
process depending on the daily positive and
negative emotional and cognitive experiences
of self-managing diabetes alongside interactions
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with HPs. Grieving takes time [62], and the
revival of grief reactions during changes in
medication have been referred to as chronic
sorrow—i.e. the reactions associated with repe-
ated losses of independence and control and
loss of identity as a healthy person, generating a
disparity between the current reality and the
desired reality [63]. Different levels of resistance
and acceptance of diabetes identity and self-
management have also been found in other
studies [64, 65].
However, all patients were engaged in
strategies to enable them to regain control of
their life, as often seen in patients with chronic
conditions [66]. Confidence in taking medicines
(i.e. self-efficacy) predicts treatment adherence
[17], but the patients in this review had differ-
ent levels of self-efficacy and coping efficacy.
Those who self-managed well were those who
were confidently able to modify daily routines
to fit medication regimes, overcoming such
challenges as polypharmacy, inconvenient
schedules and lack of reminders. Nevertheless,
intentional and unintentional non-adherence
was more common than medication adherence,
reflecting findings from other ‘adherence’ sys-
tematic reviews [3, 4].
Seemingly, accepting diabetes as a serious
disease, and therefore medicines as necessary,
and having high self- and coping-efficacy, along
with positive experiences following the initia-
tion of a new treatment are important for
medication adherence. However, when indi-
viduals do accept their medicines, they seem to
have less faith in lifestyle changes as a strategy
for self-managing diabetes, coinciding with the
findings of a longitudinal study showing that
lifestyle behaviors diminished over time in
people with T2DM [67]. However, commitment
to lifestyle measures could be associated with
individuals’ change of views and attitudes
towards their diabetes treatment, including
medications.
The findings from this review have potential
implications for both policy and practice.
Informing patients of the T2DM medication
treatments available and the inevitable progres-
sion from oral to injectable medicines could
increase awareness and allow time for grieving
so that when eventually a prescription is
required, these medicines are more easily
accepted. Moreover, if patients’ expectations of
new diabetes medicines are positively rein-
forced, i.e. good results, this could lead to a
reinforcement of positive perceptions and
acceptance of the medicines. A focus by HPs on
areas of medication concerns both prior and
during treatment is a priority for helping
patients to minimize their concerns and accept
medicines in a way that promotes better
adherence. Interventions could be designed to
promote treatment adherence by taking into
account emotional and cognitive factors and
building confidence in daily practices and social
and family support mechanisms.
In addition, the patients in this review asso-
ciated weight loss with making lifestyle chan-
ges. However, their perceptions of weight loss as
an effective strategy to manage their diabetes
varied, a finding that conflicts with current
medical evidence [68, 69]. It is unclear whether
patients were aware of the effects of the differ-
ent medicines on body weight, despite many of
them having an undesirable effect [69]. Most
patients appear to trust and accept doctors to
make decisions about their medicines. How-
ever, if they are not involved in the decision-
making process on medication treatment, it is
uncertain whether they are likely to choose a
medication based on its ability to support
weight loss or control [23], and whether know-
ing the impact of the medicine on their body
weight will affect adherence levels.
The synthesis model also has implications
for theory, proving that no single theory can be
used to fully illuminate medicine-taking
behavior by people with T2DM. Instead, various
theories can be applied, a number of which are
shown in Table 1. These include, in no partic-
ular order, the model of illness representations
[61] where emotional (guilt and grief reaction)
and cognitive factors (illness and medication-
related beliefs, perceived self- and coping-effi-
cacy) are involved in changing the view of
oneself and their practices. In line with the
Necessity–Concerns framework [13, 57],
patients showed they have ongoing concerns
about their medicines, and these concerns
coupled with their perceived need of their dia-
betes medicines could influence their
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medication adherence. Additionally, as evident
from the patients’ accounts and authors’ inter-
pretations, patients and HPs portray different
explanatory models of illness [59], which leads
to the different medical labeling in Fig. 4. For
example, what HPs see as non-adherence,
patients see as rational ways of taking control of
their life. Thus, such discrepancy in illness
models potentially can impact adherence.
Finally, the starting a new T2DM medicine, and
not just the onset of chronic illness, indicates a
biographical disruption [60]. The authors of
some studies have described psychological
insulin resistance, whereas Jenkins et al. [40]
described psychological receptiveness. How-
ever, these resistance and receptiveness con-
cepts relate to the concepts of medication
denial and acceptance based on patients’ per-
ception of diabetes seriousness. Over time,
insulin-experienced patients, i.e. those who
have taken insulin for longer than 2 years, were
more accepting of this treatment.
Strengths and Limitations
The review’s strength is reflected by the sys-
tematic identification of papers using both
broad and specific search strategies and multiple
databases. Its rigor is enhanced by the inclusion
of high-quality papers based on the CASP score
following critical appraisal by two of the
research team. The transparency and trustwor-
thiness of the findings were ascertained by
detailed discussions among the research team
about the interpretation of the findings. How-
ever the transferability of findings and concep-
tual models to patients from other countries is
limited due to our restriction on language and
focus on medication experiences from a selec-
ted group of UK participants who are medically/
pharmacologically treated and do not pay for
their prescriptions.
The intention of the synthesis was to retain a
rich context of data by looking systematically at
the influences of various contextual factors on
medication-taking behavior, such as socio-eco-
nomic status, diabetes control, body weight,
disease and treatment duration, treatment type
and use of healthcare services, as seen elsewhere
[19, 24, 70]. However, this was difficult as the
authors of many studies did not provide ade-
quate descriptions of context and the impact of
context on their findings (Table 1). We believe
such information would be useful to better
describe the medication adherence phe-
nomenon. Only a few papers provided rich and
insightful data to fully appreciate patients’
experiences and practices with diabetes medi-
cines. While there were only two longitudinal
studies, most studies were based on peoples’
memories of past experiences and their views
after medication changes had occurred. The
synthesis related to OGLDs was based on two
studies, which were mainly conducted by the
same group of authors. Furthermore, the pro-
cess of synthesizing is inherently interpretive,
so other reviewers may produce difference
conceptual frameworks. Nonetheless, 19 papers
provided sufficient data to reach a ‘‘line-of-ar-
gument’’ resonating findings from other pub-
lished reviews [14, 17, 20, 22, 24, 71]. This
suggests that our findings are triangulated and
credible.
CONCLUSION
This meta-ethnographic review provides new
insights into T2DM patient’ reasons for poor
adherence and identifies specific practical issues
which can help in the development of patient-
centered interventions. The models demon-
strate how the theories could be interlinked and
applied to future research. Further research is
needed to develop informed patient-centered
approaches to improving treatment adherence
among people with T2DM. Research should
focus on understanding how patients’ views of
their medicines change over time based on
longitudinal studies and how their experiences
have an impact on adherence by investigating
factors such as glycemic control and body
weight changes and type of treatment, includ-
ing other injectable medicines. Without know-
ing what causes changes in peoples’ perceptions
and behaviors there will always be uncertainty
as to which interventions can help support
patients to improve their health and quality of
life.
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